Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.
David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.
The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.
A sharp decline has been observed in the overall rate of men receiving treatment for prostate cancer.
Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.
William Oh, MD, discusses the continued significant of docetaxel in advanced prostate cancer.
The FDA has granted a priority review to a supplemental new drug application for the use of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
Adding enzalutamide to abiraterone acetate failed to improve progression-free survival versus abiraterone alone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.